 BOSTON, Nov. 30, 2020 GLOBE NEWSWIRE -- Imara Inc. Nasdaq: IMRA, a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that clinical data from the ongoing IMR-687 Phase 2a open label extension OLE clinical trial in adult patients with sickle cell disease SCD will be presented at the 62 nd American Society of Hematology ASH Annual Meeting and Exposition to be held virtually December 5-8, 2020. 